Salmedix, acquired by Cephalon Inc. in June 2005, focused on the development of promising oncology drugs for hematologic cancers. The company’s strategy was to develop compounds with prior human clinical data in order to facilitate a shorter, less costly development path. At the time of investment by H.I.G. Venture Partners, their lead pipeline product, SDX-105, was in Phase 2/3 clinical development for the treatment of non-Hodgkin’s lymphoma. Following the acquisition of Salmedix, SDX-105 went on to become a blockbuster for Cephalon as Treanda® generating over $1 billion in sales.

For more information visit: